Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Acting to bolster its drug pipeline for myasthenia gravis, UCB has agreed to buy Ra Pharmaceuticals in a deal valued at $2.1 billion. The acquisition will place Ra’s zilucoplan, a peptide in Phase III clinical trials to treat the neuromuscular disease, beside UCB’s rozanolixizumab, an antibody also in Phase III trials against the disease. UCB will also net Ra’s Extreme Diversity technology for producing synthetic macrocyclic peptides. UCB plans to keep Ra’s Cambridge, Massachusetts, research center in place.
This article has been sent to the following recipient: